Preterm birth is the leading cause of perinatal morbidity
|
|
- Philippa Blair
- 5 years ago
- Views:
Transcription
1 Nifedipine Compared With Atosiban for Treating Preterm Labor A Randomized Controlled Trial Raed Salim, MD, Gali Garmi, MD, Zohar Nachum, MD, Noah Zafran, MD, Shira Baram, MD, and Eliezer Shalev, MD OBJECTIVE: To compare the tocolytic efficacy and tolerability of nifedipine with that of atosiban among pregnant women with preterm labor. METHODS: Pregnant women admitted with preterm labor and intact membranes between 24 and 33 weeks 6 days of gestation, between January 2008 and December 2011, were randomly assigned to either atosiban or nifedipine treatment. Assigned treatment was planned for up to 48 hours. If progress was determined after 1 hour or more, a crossover of the study drugs was performed. The primary outcome was to estimate the tocolytic efficacy and tolerability profile that was assessed in terms of the proportion of women who were not delivered and did not require an alternate tocolytic agent within 48 hours. Secondary outcomes were gestational age at delivery and neonatal morbidity. RESULTS: Seventy-five women in the nifedipine group and 70 in the atosiban group were included and analyzed. Baseline demographic and obstetric characteristics were comparable. Forty-eight (68.6%) women allocated to atosiban and 39 (52%) to nifedipine did not deliver and did not require an alternate agent at 48 hours respectively (P5.03). At 7 days from enrollment, 55 (78.6%) women allocated to atosiban and 67 (89.3%) to nifedipine remained undelivered with or without From the Department of Obstetrics and Gynecology, Emek Medical Center, Afula, and Rappaport Faculty of Medicine, Technion, Haifa, Israel. Supported by the Department of Obstetrics and Gynecology, Emek Medical Center, Afula. The authors thank Paula S. Herer, MSc, biostatistician, for assisting in the statistical analysis. Corresponding author: Raed Salim, MD, Department of Obstetrics and Gynecology, Emek Medical Center, Afula, Israel 18101; salim_ra@ clalit.org.il. Financial Disclosure The authors did not report any potential conflicts of interest by The American College of Obstetricians and Gynecologists. Published by Lippincott Williams & Wilkins. ISSN: /12 a rescue agent (P5.02). Mean gestational age at delivery was 35.2 (63.0) and 36.4 (62.8) weeks among the atosiban and nifedipine groups, respectively (P5.01). Mean birth weight and neonatal morbidity were comparable. CONCLUSIONS: Atosiban has fewer failures within 48 hours. Nifedipine may be associated with a longer postponement of delivery. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT (Obstet Gynecol 2012;120: ) DOI: LEVEL OF EVIDENCE: I Preterm birth is the leading cause of perinatal morbidity and mortality. 1 Both morbidity and mortality rates are inversely related to gestational age at delivery and each day of delay, particularly before 28 weeks of gestation, increases the survival rate by 3%. 2 Spontaneous preterm labor with intact membranes is responsible for approximately one-third of all cases of preterm birth. 3 Between 24 and 33 weeks of gestation, the benefits of tocolytic therapy generally outweigh the risk of maternal, fetal, or both complications and these agents should be initiated provided no contraindications exist. 2 Comparison studies of the effectiveness of different tocolytic drugs showed comparable results. All have demonstrated a relative benefit that consists mainly of prolonging the gestational age for at least 48 hours, which may allow for the administration of corticosteroids and allow maternal transport to a tertiary care center. 4 There is no clear first-line tocolytic drug to manage preterm labor. The optimal agent would combine the highest tolerability and the highest proportion of delayed deliveries. 2 Most currently available tocolytic agents carry inherent risks of undesirable adverse effects caused by their nonselective pharmacologic actions on maternal or fetal organs. VOL. 120, NO. 6, DECEMBER 2012 OBSTETRICS & GYNECOLOGY 1323
2 Treatment with b-adrenergic receptor agonists may be accompanied occasionally with severe adverse effects. 2 The efficacy of magnesium sulfate is uncertain, 5,6 and concerns regarding adverse fetal effects of cyclooxygenase inhibitors limited its use particularly at a gestational age above weeks. 2 Compared with all of these agents, both nifedipine and atosiban were found to be superior or comparable to b-adrenergic receptor agonists for tocolysis. In addition, both were associated with fewer fetal and maternal adverse effects. 7,8 To determine the ideal first-line tocolytic agent, we aimed in this study to compare the tocolytic efficacy and tolerability of nifedipine with that of atosiban among pregnant women with preterm labor. PATIENTS AND METHODS This randomized study was held at a single university teaching medical center between January 2008 and December Women with preterm labor and intact membranes diagnosed between 24 weeks 0 days and 33 weeks 6 days of gestation were included and randomly assigned to either the atosiban group or the nifedipine group. Preterm labor was defined as the presence of four or more uterine contractions, each lasting 30 seconds or more within 30 minutes confirmed by external tocography and accompanied with cervical effacement of at least 50% and cervical dilatation of 0 4 cm among nulliparous women or 1 4 cm among multiparous women. Gestational age was confirmed by either a documented first-trimester ultrasound scan or by a reliable menstrual date confirmed by ultrasonography performed before 20 weeks of gestation. Exclusion criteria included rupture of membranes, vaginal bleeding resulting from placenta previa or placental abruption, fever above 38 C, severe preeclampsia, maternal cardiovascular or liver diseases, systolic blood pressure less than 90 mm Hg, known uterine malformation, intrauterine growth restriction below the fifth percentile, nonreassuring fetal status, antepartum diagnosis of major fetal malformations, multiple gestations other than twins (triplets or greater), and fetal death. After random allocation to a treatment group, women received atosiban or nifedipine as follows: 1. Atosiban was given as a single loading intravenous dose, 6.75 mg in 0.9% sodium chloride solution, followed by an intravenous infusion of 300 micrograms/min in 0.9% sodium chloride solution for the first 3 hours and then 100 micrograms/min for another 45 hours. The choice of the dose regimen for atosiban was consistent with the recommendations of the product labeling. 2. Nifedipine was given as a loading dose of 20 mg orally followed by another two doses of 20 mg, minutes apart as needed. Maintenance was started after 6 hours with mg four times a day for a total of 48 hours. Women were randomly assigned to receive intravenous therapy with atosiban or oral nifedipine for at least 1 hour. Assigned treatment was planned for up to 48 hours. Maintenance therapy after the first 48 hours was not provided. In addition, tocolytic drugs were discontinued when progression to a cervical dilatation of 5 cm or more or rupture of membranes occurred. Other tocolytic agents were not permitted concomitantly. Labor was considered to have progressed and the woman became eligible for rescue tocolysis if either of the following occurred after at least 1 hour of observation during treatment: 1. increase or no change in the frequency of the contractions, or 2. an increase in cervical dilatation of 1 cm or more. If progress was determined after 1 hour or more, but before 48 hours, or if adverse effects of the drug were noted, a crossover of the study drugs was performed and the alternative tocolytic drug (rescue treatment) was initiated. In cases in which both drugs failed before 48 hours of admission, and the gestational age was 28 weeks or less, indomethacin, as a second rescue agent, was then initiated (two 100-mg per rectum tablets, 1 hour apart, followed by oral tablets of 25 mg four times a day for the rest of the 48 hours). Women with successful tocolysis but with a recurrence of preterm labor at any time after the cessation of the study drug were treated again with the same assigned agent, provided that all eligibility criteria were still met. Prophylactic antibiotics for group B streptococcus and corticosteroids were administered according to standard clinical indications. Uterine contractions were monitored continuously by an external tocodynamometer for 2 4 hours after initiation of the study drug followed by two to three times a day for minutes. The primary outcome was to estimate the tocolytic efficacy and tolerability profile that was assessed in terms of the proportion of women who were not delivered and who did not require an alternate tocolytic agent within 48 hours after initiation of the study drug. Secondary outcomes included the proportion of women who did not deliver and did not require an alternate tocolytic agent at 7 days after initiation of therapy. In addition, tocolytic effectiveness was assessed in terms of the total number of women in the intent-to-treat population who had not been delivered at 48 hours and at 7 days after starting treatment, number of preterm 1324 Salim et al Nifedipine or Atosiban for Preterm Labor OBSTETRICS & GYNECOLOGY
3 deliveries, and the latency period from enrollment until delivery. Safety was assessed by assessing maternal adverse effects that included maternal tachycardia defined as heart rate above 120 beats per minute, hypotension defined as systolic blood pressure less than 90 mm Hg, feeling of palpitations, headache, nausea, vomiting, itching, and rash. Other secondary outcomes examined were gestational age at delivery and neonatal morbidity and mortality related to prematurity that were assessed until either discharge from the hospital or neonatal death. Randomization of the groups was performed in blocks of 10 using a computer randomization sequence generation program and the randomization results were kept in the labor and delivery ward in a closed study box. The sequence was concealed until intervention was assigned, ie, just before administrating the tocolytic drug. Because the study drugs were administered by different roots, blinding of participants or care providers was not performed. All authors took part in enrolling and assigning women to interventions. The study was approved by the local institutional review board, Emek Medical Center, and the Israeli ministry of health. Each woman signed an informed consent. An intent-to-treat analysis was performed. To assess the difference in the two treatment groups demographic and clinical data, the Wilcoxon ranksum test was used for continuous data and the x 2 or Fisher s exact tests where appropriate were used for the categorical data. Adjusted odds ratio and 95% confidence interval were calculated for the tocolytic efficacy and tolerability and for the tocolytic effectiveness at 48 hours and 7 days by multiple logistic regression analysis. The same calculations were performed for other secondary outcomes. Adjustment was made for twins, previous preterm delivery, progesterone treatment, closed cervix at presentation, and additional tocolytics. Kaplan-Meier survival analysis was also performed for comparing gestational age at birth using the intent-to-treat protocol. Breslow s test (Gehan s generalized Wilcoxon test) was used to compare the survival time of the two treatments. This test gives greater weight for differences in treatment at the beginning of the study than at the end of the study time. Sample size was based on the results of a previous multicenter study that our department took part in 8 and which showed that the tocolytic efficacy and tolerability of atosiban is 71.4% at 48 hours. Accordingly 70 women per group were sufficient to show a difference of 25% in the tocolytic efficacy and tolerability of atosiban as compared with nifedipine (ie, 71.4% to 46.4%) with a level of significance of 95% (a50.05) and a power of 80% (b50.2). RESULTS One hundred forty-nine women were randomized during the study period. Three women were excluded as a result of cervical progression beyond 4 cm before the study drug was initiated and one woman allocated to atosiban withdrew her consent before therapy. All other women were included and analyzed, 75 women in the nifedipine group and 70 in the atosiban group (Fig. 1). Baseline demographic and obstetric characteristics were comparable between the groups (Table 1). None of the women had a cervical cerclage. The tocolytic efficacy and tolerability profile at 48 hours was significantly higher among women allocated to atosiban as compared with the nifedipine (Table 2). Of all women allocated to atosiban, 48 Assessed for eligibility N=172 Randomized n=149 Excluded: n=23 Not meeting inclusion criteria: 1 Declined to participate: 22 Fig. 1. Randomization and analysis of women included in the study. Salim. Nifedipine or Atosiban for Preterm Labor. Obstet Gynecol Did not receive atosiban: n=2 Progressed beyond 4 cm: 1 Elected to discontinue: 1 Allocated to atosiban n=72 Received atosiban n=70 Analyzed n=70 Allocated to nifedipine n=77 Received nifedipine n=75 Analyzed n=75 Did not receive nifedipine: n=2 Progressed beyond 4 cm: 2 VOL. 120, NO. 6, DECEMBER 2012 Salim et al Nifedipine or Atosiban for Preterm Labor 1325
4 Table 1. Baseline Maternal Demographic and Obstetric Characteristics According to Treatment Allocation Nifedipine (n575) Atosiban (n570) P Age (y) 27 (19 48) 28 (20 44).88 Body mass index (kg/m 2 ) (pregestation) 21.4 ( ) 22.6 ( ).21 Ethnic group.16 Arab 32 (42.7) 38 (54.3) Jewish 43 (57.3) 32 (45.7) Gravidity 2 (1 9) 2 (1 9).10 Parity (49.3) 25 (35.7) 1 or more 38 (50.7) 45 (64.3) Past preterm delivery (84.0) 55 (78.6) 1 or more 12 (16.0) 15 (21.4) Gestational age at randomization (wk) 31.8 ( ) 31.1 ( ).24 Gestational status according to no. of fetuses at randomization.97 Singletons at 28 wk of gestation or before 5 (6.7) 6 (8.6) Singletons after 28 wk of gestation 47 (62.7) 43 (61.4) Twins at 28 wk of gestation or before 5 (6.7) 4 (5.7) Twins after 28 wk of gestation 18 (24.0) 17 (24.3) Progesterone treatment 17 (22.7) 16 (22.9).98 Past spontaneous preterm labor 7 (41.2) 8 (50.0) Short cervix 10 (58.8) 8 (50.0) Maternal disease None 53 (70.7) 44 (62.9).38 Gestational hypertensive disorders 3 (4.0) 6 (8.6).31 Diabetes in pregnancy 7 (9.3) 9 (12.9).60 Thrombophilia 3 (4.0) 2 (2.9)..99 Urinary tract infection 8 (10.7) 8 (11.4)..99 Thyroid disease 2 (2.7) 5 (7.1).26 Epilepsy 0 (0.0) 1 (1.4).48 Contraction frequency/30 min 9 (4 16) 9 (4 18).78 Cervical dilatation (cm) 1.5 (0 3) 1.5 (0 4).12 Percentage of cervical effacement 70 (50 100) 70 (50 100).36 Data are median (range) or n (%) unless otherwise specified. (68.6%, 95% confidence interval [CI] ) did not deliver and did not require an alternate tocolytic agent at 48 hours as compared with 39 (52.0%, 95% CI ) among the nifedipine group (P 5.03). This difference was not significant at 7 days from enrollment. Tocolytic effectiveness that was assessed in term of the proportions of women in the intent-totreat population who had not been delivered at 48 hours after treatment regardless of whether a crossover was made or not did not differ between the groups irrespective of gestational age at enrollment or the number of fetuses (Table 2). Nevertheless, the proportion of women who remained undelivered at 7 days had a singleton and enrolled at 28 weeks of gestation or more was significantly higher among the nifedipine compared with the atosiban group (P 5.02) (Table 2). Of all women who had a crossover to the alternate agent within 48 hours from enrollment, only one was the result of adverse effects within the nifedipine group. Two women in each group required the use of a third line, ie, indomethacin. Nine women (12.9%, 95% CI ) in the atosiban group and 11 (14.7%, 95% CI ) in the nifedipine group received one or more additional treatments, 48 hours or more after enrollment (P 5.9). There was no difference between the groups with any particular maternal morbidity investigated (Table 3); however, the number of women with any adverse effect was significantly higher among the nifedipine (22.7%, 95% CI ) compared with the atosiban group (7.1%, 95% CI ) (adjusted odds ratio [OR] 4.18, 95% CI , P 5.01). Women with any cardiovascular adverse effect (hypotension, tachycardia, or palpitation) was also significantly higher among the nifedipine (17.3%, 95% CI ) compared with the atosiban group (4.3%, 95% CI ) (adjusted OR 5.14, 95% CI , P 5.03). Gestational age at delivery was significantly higher among the nifedipine group compared with the atosiban group, regardless of whether labor was initiated spontaneously or not (Table 4). The number of women delivered preterm, ie, less than 37 weeks of 1326 Salim et al Nifedipine or Atosiban for Preterm Labor OBSTETRICS & GYNECOLOGY
5 Table 2. Tocolytic Efficacy and Tolerability and Tocolytic Effectiveness of Atosiban and Nifedipine at 48 Hours and at 7 Days Nifedipine (n575) Atosiban (n570) Adjusted Odds Ratio* 95% CI Adjusted P* Tocolytic efficacy and tolerability No failure at 48 h 39 (52.0) 48 (68.6) At 28 wk of gestation or before 6/10 (60.0) 7/10 (70.0) After 28 wk of gestation 33/65 (50.8) 41/60 (68.3) No failure at 7 d 37 (49.3) 44 (62.9) At 28 wk of gestation or before 5/10 (50.0) 6/10 (60.0) After 28 wk of gestation 32/65 (49.2) 38/60 (63.3) Tocolytic effectiveness Not yet delivered at 48 h 69 (92.0) 60 (85.7) At 28 wk of gestation or before 9/10 (90.0) 9/10 (90.0) After 28 wk of gestation 60/65 (92.3) 51/60 (85.0) Not yet delivered at 7 d 67 (89.3) 55 (78.6) At 28 wk of gestation or before 9/10 (90.0) 8/10 (80.0) After 28 wk of gestation 58/65 (89.2) 47/60 (78.3) Tocolytic effectiveness Not yet delivered at 48 h 69 (92.0) 60 (85.7) Singletons 47/52 (90.4) 43/49 (87.8) Twins 22/23 (95.7) 17/21 (81.0) Not yet delivered at 7 d 67 (89.3) 55 (78.6) Singletons 47/52 (90.4) 39/49 (79.6) Twins 20/23 (87.0) 16/21 (76.2) CI, confidence interval. Data are n (%) or n/n (%) unless otherwise specified. * Adjustment was made for twins, previous preterm delivery, progesterone treatment, closed cervix, and additional tocolytics. gestation, was significantly higher among the atosiban group (66.2%, 95% CI ) as compared with the nifedipine group (43.2%, 95% CI , P 5.007). The incidence of deliveries at less than 34 weeks of gestation did not differ significantly between the groups (Table 4). Among the nifedipine group, 40 (53.3%, 95% CI ) women used the assigned drug only (delivery was delayed for more than 48 hours without a rescue or dilatation progressed to more than 5 cm within 1 hour from enrollment) compared with 54 (77.1%, 95% CI ) women among the atosiban group Table 3. Maternal Morbidity According to Treatment Allocation Nifedipine (n575) Atosiban (n570) Adjusted Odds Ratio* 95% CI Adjusted P* Hypotension 8 (10.7) 2 (2.9) Tachycardia 4 (5.3) 1 (1.4) Palpitation 1 (1.3) 0 (0.0) Headache 4 (5.3) 2 (2.9) Nausea 1 (1.3) 0 (0.0) Vomiting 0 (0.0) 0 (0.0) Pruritus 1 (1.3) 0 (0.0) Local irritation 0 (0.0) 0 (0.0) Rush 0 (0.0) 0 (0.0) Women with any morbidity 17 (22.7) 5 (7.1) Readmission before 34 wk of gestation 17 (22.7) 18 (25.7) Mode of delivery.64 Vaginal 71 (94.7) 65 (92.9) Cesarean 4 (5.3) 5 (7.1) CI, confidence interval. Data are n (%) unless otherwise specified. * Adjustment was made for twins, previous preterm delivery, progesterone treatment, closed cervix, and additional tocolytics. VOL. 120, NO. 6, DECEMBER 2012 Salim et al Nifedipine or Atosiban for Preterm Labor 1327
6 Table 4. Perinatal Outcomes of Pregnancies According to Treatment Allocation Nifedipine Atosiban Adjusted Odds Ratio and Coefficient* (95% CI) Adjusted P* n575 women n570 women Gestational age at (37, 28 41) (22.14 to 20.27).01 delivery (wk) (35, ) Gestational age of (37.2, 28 41) (22.18 to 20.30).01 spontaneous deliveries (wk) (35.2, ) Days from enrollment to (35, 1 94) (32, 1 70) ( to 1.02).1 spontaneous delivery Spontaneous deliveries 31 (43.1) 45 (66.2) 2.78 ( ).007 before 37 wk of gestation Spontaneous deliveries 12 (16.7) 19 (27.9) 2.12 ( ).08 before 34 wk of gestation Spontaneous deliveries 1 (1.4) 2 (2.9) 3.40 ( ).35 before 28 wk of gestation n598 neonates n591 neonates Birth weight (g) 2, , ( to 72.2).28 (2,351, 920 3,800) (2,243, 750 3,600) Neonates with birth weights 54 (55.1) 60 (65.9) 2.50 ( ).15 less than 2,500 g Neonatal intensive care 29 (29.6) 46 (50.5) 2.81 ( ).002 unit admission Hospitalized days (2.0, 1 95) (11.0; 2 97) 5.5 ( ).04 CI, confidence interval. Data are mean6standard deviation (median range) or n (%) unless otherwise specified. * Linear regression was performed on the continuous variables (beta coefficient is shown) and logistic regression for the binary variables (odds ratio is shown). Adjustment was made for twins, previous preterm delivery, progesterone treatment, closed cervix, and additional tocolytics. (OR 2.9, 95% CI , P 5.003). Median gestational age at delivery within these pure groups was also higher among the nifedipine group (37.6 weeks, range weeks) compared with the atosiban group (35.6 weeks, range weeks, P 5.02). Kaplan-Meier survival analysis of the gestational age at birth showed that there was a statistically significant difference between the two treatment groups (Breslow P 5.04). Median gestational age for women allocated to the nifedipine group was 37 weeks (95% CI ) and 35 weeks (95% CI ) for women allocated to the atosiban group (Fig. 2). Similar results were found when stratifying for gestational age at enrollment (P 5.03). The number of neonates admitted to the neonatal intensive care unit (NICU) and length of stay after delivery were significantly higher among the atosiban group as compared with the nifedipine group (Table 4). Overall, neonatal morbidity related to prematurity was comparable between the groups, although the incidence of respiratory distress syndrome and mechanical ventilation among singletons was more than double within the atosiban group as compared with the nifedipine group; however, this Not delivered (%) Nifedipine Atosiban Gestational age at birth (weeks) Fig. 2. Statistical curves for comparing gestational age at birth using the intent-to-treat protocol. There was a statistically significant difference between the two treatment groups (P5.04). Salim. Nifedipine or Atosiban for Preterm Labor. Obstet Gynecol Salim et al Nifedipine or Atosiban for Preterm Labor OBSTETRICS & GYNECOLOGY
7 difference was not significant. There were no neonatal deaths in either study group (Table 5). DISCUSSION The present study was undertaken to compare the tocolytic efficacy and tolerability profile of nifedipine as compared with atosiban among pregnant women admitting with signs of preterm labor between 24 and 34 weeks of gestation. Atosiban was found to be superior to nifedipine in terms of the proportion of women who did not give birth and who did not require an alternate tocolytic agent within 48 hours from the initiation of therapy. In addition, atosiban was better tolerated by women compared with nifedipine. Both drugs were comparable in terms of the total number of women, in the intent-to-treat analysis, who did not deliver at 48 hours after enrollment. However, the proportion of women who had a singleton and enrolled at 28 weeks of gestation or more and who had remained undelivered at 7 days was significantly higher among the nifedipine compared with the atosiban group. Additionally, women assigned to nifedipine had a lower rate of preterm deliveries and delivered 1 week more than women assigned to atosiban. As a result, probably, more neonates in the atosiban group were hospitalized at the NICU and for a longer time. Furthermore, the incidence of respiratory distress syndrome and mechanical ventilation among singletons was more than two times greater within the atosiban group as compared with the nifedipine group, although this difference was not significant. Preterm birth is responsible for approximately 75% of all neonatal deaths and 50% of childhood neurologic morbidities. 9,10 It is also associated with both high immediate and long-term costs after discharge from the hospital. 11 Postponing delivery for 48 hours to administer corticosteroids or to gain critical time to allow the transfer of women to a center with NICU facilities or both is the crucial goal to achieve with tocolytic drugs in cases of a threatening preterm delivery. Several agents have been used to inhibit uterine contractility, but it remains unclear what is the first-line tocolytic agent. Betamimetics reduce the rate of preterm delivery within 48 hours; however, maternal adverse effects are considerable. 7 Magnesium sulfate has not been proven to be an effective tocolytic agent at delaying birth, and its use had been reported to be associated with an increased incidence of adverse effects and risk of neonatal mortality. 12 Concerns regarding adverse effects of cyclooxygenase inhibitors on the fetal kidneys, ductus arteriosus, increased risk of neonatal intraventricular hemorrhage, and necrotizing enterocolitis have limited its use, especially at a gestational age above weeks. 2 Nifedipine and atosiban were found to be comparable to betamimetics and both were associated with significantly fewer maternal adverse effects as compared with betamimetics. 7,8 Atosiban is currently licensed in Europe but not in the United States. As a result of its placebo-like maternal-fetal adverse effect profile, the Royal College of Obstetricians and Gynecologists suggested considering atosiban as a first-line tocolytic agent. 2,8,13,14 On the other hand, several systematic reviews and metaanalysis confirmed that in addition to its comparable effect to betamimetics in delaying delivery for more than 48 hours, nifedipine reduced the incidence of preterm delivery, and more notably reduced neonatal morbidity, including respiratory distress syndrome and NICU admissions. 7,15 Although nifedipine is not Table 5. Neonatal Morbidity Among Singletons and Twins Singletons Twins Nifedipine (n552) Atosiban (n549) P Nifedipine (n546) Atosiban (n542) P Apgar score less than 7 at 5 min 2 (3.8) 0 (0.0).50 0 (0.0) 1 (2.4).48 Sepsis 1 (1.9) 1 (2.0) (4.3) 1 (2.4)..99 Respiratory distress syndrome 2 (3.8) 5 (10.2).26 5 (10.9) 4 (9.5)..99 Mechanical ventilation 4 (7.8) 8 (16.3).23 6 (13.0) 5 (11.9)..99 Apnea 0 (0.0) 1 (2.0).49 1 (2.2) 0 (0.0)..99 Intraventricular hemorrhage 2 (3.8) 2 (4.1) (0.0) 2 (4.8).23 Necrotizing enterocolitis 0 (0.0) 1 (2.0).49 0 (0.0) 3 (7.1).11 Retinal disorder 0 (0.0) 1 (2.0).49 1 (2.2) 1 (2.4)..99 Bradycardia 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.4).48 No. of neonates with any morbidity* 4 (7.7) 9 (18.4).11 9 (19.6) 9 (21.4)..99 Neonatal mortality 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) Data are n (%) unless otherwise specified. * Singleton, adjusted odds ratio (OR) 2.80, 95% confidence interval (CI) , P5.11; twins, adjusted OR 1.29, 95% CI , P5.65. Adjustment made for twins, previous preterm delivery, progesterone treatment, closed cervix, and additional tocolytics. VOL. 120, NO. 6, DECEMBER 2012 Salim et al Nifedipine or Atosiban for Preterm Labor 1329
8 licensed as a tocolytic agent, the results of these metaanalyses and others brought some authors to suggest that nifedipine appears to meet several characteristics of an ideal tocolytic agent and may be considered a first-line tocolytic agent. 15,16 In view of this, the question of which agent should be the first line, atosiban or nifedipine, is still a subject of controversy in many articles. A meta-analysis with an indirect comparison of nifedipine and atosiban showed that the former was associated with a nonsignificant increase in the number of women whose delivery was delayed for at least 48 hours and a significant reduction in respiratory distress syndrome compared with atosiban. Because biases may go along with results of a meta-analysis with an indirect comparison, the authors strengthen the need for better evidence from randomized trials directly comparing nifedipine and atosiban. 17 Following the publication of this meta-analysis, two small, underpowered studies that compared the efficacy and safety of atosiban and nifedipine in preventing or delaying preterm labor were published. According to the results of both studies, the efficacy of both medications was the same, but adverse effects of nifedipine were significantly more than atosiban. 18,19 In this study, atosiban as compared with nifedipine was found to be superior in terms of the proportion of women who did not deliver and who did not require an alternate agent within 48 hours after initiation of therapy. This effect was pronounced, particularly among women admitted at a gestational age of 28 weeks or more. Similar results regarding the inferiority of atosiban at less than 28 weeks of gestation were reported by others. 1,19 This observation may be attributed to the fact that lower concentrations of oxytocin receptors are present at an earlier gestational age. 20 In addition, the onset of preterm uterine contractions, particularly the very preterm, may involve other pathways that do not bring into play oxytocin. 21 On the other hand, nifedipine as compared with atosiban was found to be associated with a higher mean gestational age at delivery, a lower incidence of preterm deliveries, and, probably accordingly, lead to a lower incidence of respiratory distress syndrome, NICU admissions, and a shorter length of stay. This effect was valid among women assigned to nifedipine regardless of whether they received nifedipine only or needed a rescue agent. Although both drugs were discontinued at 48 hours from enrollment, these repeated observations regarding the superiority of nifedipine may indicate that it probably has an additional long-acting effect that may involve other pathways in the pathophysiologic process of preterm birth beyond that achieved by impeding acute uterine contractions. The limitations of the current study are worth mentioning. First, although we conducted a priori sample size calculation to ensure adequate power to examine the efficacy and tolerability of the tocolytic drugs, we may be underpowered to detect small differences in terms of secondary outcomes. Second, we did not use a third agent as a first rescue drug; rather, we chose to make a crossover between the study drugs. The decision was based on medical and ethical issues, because both study drugs are considered to have the greatest maternal and fetal safety profile compared with other medications. The choice of the first-line tocolytic agent in terms of safety profile, efficacy, and costs is a topic of debate. An ideal tocolytic agent is supposed to delay delivery with minimal maternal and fetal adverse effects at low costs. None of the tocolytic medications available fulfills all these criteria. According to the current study, atosiban has fewer failures within 48 hours and probably a better maternal safety profile, both of which favor its use as a first line, particularly in cases in which maternal transport to a tertiary center is being planned or among women with cardiovascular disorders. On the other hand, the overall low incidence of maternal adverse effects associated with the use of nifedipine, the oral route of administration, low costs compared with atosiban, better effectiveness, and a possible efficacy in reducing neonatal morbidity favor its use as a first line, ie, the first agent to start with, among the remaining cases. REFERENCES 1. Romero R, Sibai BM, Sanchez-Ramos L, Valenzuela GJ, Veille JC, Tabor B, et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, doubleblind, placebo-controlled trial with tocolytic rescue. Am J Obstet Gynecol 2000;182: Meloni A, Melis M, Alba E, Deiana S, Atzei A, Paoletti AM, et al. Medical therapy in the management of preterm birth. J Matern Fetal Neonatal Med 2009;22(suppl): Arias F, Tomich P. Etiology and outcome of low birth weight and preterm infants. Obstet Gynecol 1982;60: Management of preterm labor. Practice Bulletin No American College of Obstetricians and Gynecologists. Obstet Gynecol 2012;119: Grimes DA, Nanda K. Magnesium sulfate tocolysis: time to quit. Obstet Gynecol 2006;108: Mittendorf R, Pryde PG. A review of the role for magnesium sulphate in preterm labour. BJOG 2005;112(suppl): Conde-Agudelo A, Romero R, Kusanovic JP. Nifedipine in the management of preterm labor: a systematic review and metaanalysis. Am J Obstet Gynecol 2011;204:134.e Moutquin JM, Sherman D, Cohen H, Mohide PT, Hochner- Celnikier D, Fejgin M, et al. Double-blind, randomized, controlled 1330 Salim et al Nifedipine or Atosiban for Preterm Labor OBSTETRICS & GYNECOLOGY
9 trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. Am J Obstet Gynecol 2000;182: Slattery MM, Morrison JJ. Preterm delivery. Lancet 2002;360: Hack M, Dandruff AA. Outcomes of children of extremely low birthweight and gestational age in the 1990 s. Early Hum Dev 1999;53: Petrou S, Mehta Z, Hockley C, Cook-Mozaffari P, Henderson J, Goldacre M. The impact of preterm birth on hospital inpatient admissions and costs during the first 5 years of life. Pediatrics 2003;112: Crowther CA, Hiller JE, Doyle LW. Magnesium sulphate for preventing preterm birth in threatened preterm labour. The Cochrane Database of Systematic Reviews 2002, Issue 4. Art. No.: CD DOI: / CD Usta IM, Khalil A, Nassar AH. Oxytocin antagonists for the management of preterm birth: a review. Am J Perinatol 2011;28: Petraglia F, Visser GH. Prevention and management of preterm labour. J Matern Fetal Neonatal Med 2009;22(suppl): King JF, Flenady V, Papatsonis D, Dekker G, Carbonne B. Calcium channel blockers for inhibiting preterm labour; a systematic review of the evidence and a protocol for administration of nifedipine. Aust N Z J Obstet Gynaecol 2003;43: Tsatsaris V, Papatsonis D, Goffinet F, Dekker G, Carbonne B. Tocolysis with nifedipine or beta-adrenergic agonists: a metaanalysis. Obstet Gynecol 2001;97: Coomarasamy A, Knox EM, Gee H, Song F, Khan KS. Effectiveness of nifedipine versus atosiban for tocolysis in preterm labour: a meta-analysis with an indirect comparison of randomised trials. BJOG 2003;110: Kashanian M, Akbarian AR, Soltanzadeh M. Atosiban and nifedipin for the treatment of preterm labor. Int J Gynaecol Obstet 2005;91: Al-Omari WR, Al-Shammaa HB, Al-Tikriti EM, Ahmed KW. Atosiban and nifedipine in acute tocolysis: a comparative study. Eur J Obstet Gynecol Reprod Biol 2006;128: Fuchs AR, Fuchs F, Husslein P, Soloff MS. Oxytocin receptors in the human uterus during pregnancy and parturition. Am J Obstet Gynecol 1984;150: Cole RM, Lamont RF. Current perspectives on drug treatment for preterm labour. J Obstet Gynaecol 1998;18: Harold A. Kaminetzky Award The American College of Obstetricians and Gynecologists (the College) and Obstetrics & Gynecology have established the Harold A. Kaminetzky Award to recognize the best paper from a non-u.s. researcher each year. Dr. Harold A. Kaminetzky, former College Secretary and President, as well as Vice President, Practice Activities, has had a long career as editor of major medical journals. His last editorship was as Editor of the International Journal of Gynecology and Obstetrics. Dr. Kaminetzky has also had a long interest in international activities. The Harold A. Kaminetzky Award winner will be chosen by the editors and a special committee of former Editorial Board members. The recipient of the award will receive $2,000. Read the journal online at 1/2010 VOL. 120, NO. 6, DECEMBER 2012 Salim et al Nifedipine or Atosiban for Preterm Labor 1331
ATOSIBAN VERSUS NIFEDIPIN FOR THE MANAGEMENT OF PRETERM LABOR: A PROSPECTIVE STUDY
AAMJ, VOL11, NO4, OCT 2013 SUPLL 2 ATOSIBAN VERSUS NIFEDIPIN FOR THE MANAGEMENT OF PRETERM LABOR: A PROSPECTIVE STUDY Tarek R. Abbas Department of Obstetrics and Gynecology, Al-Azhar Faculty of Medicine,
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Acute and Maintenance Page 1 of 11 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Acute and Maintenance Subcutaneous and Intravenous Tocolysis Professional
More informationMedical Policy. MP Acute and Maintenance Tocolysis
Medical Policy MP 5.01.07 BCBSA Ref. Policy: 5.01.07 Last Review: 08/30/2017 Effective Date: 08/30/2017 Section: Prescription Drugs End Date: 08/19/2018 Related Policies 4.01.16 Progesterone Therapy as
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): December 8, 2003 Most Recent Review Date (Revised): July 22, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More informationBy Dr.Asmaa Al sanjary
By Dr.Asmaa Al sanjary Preterm delivery is defined by a birth occurring before 37 completed weeks of gestation. Prematurity is multifactorial and its incidence has increased during the last decade in most
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Acute and Maintenance Tocolysis Page 1 of 14 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Acute and Maintenance Tocolysis Professional Institutional Original
More informationTO COMPARE THE EFFECTIVENESS OF NIFEDIPINE AND GLYCERYL TRINITRATE PATCH IN PREVENTION OF PRETERM LABOUR ABSTRACT
ORIGINAL ARTICLE TO COMPARE THE EFFECTIVENESS OF NIFEDIPINE AND GLYCERYL TRINITRATE PATCH IN PREVENTION OF PRETERM LABOUR 1-3 Department of Gynae & Obstetrics, Lady Reading Hospital, Peshawar - Pakistan.
More informationNifedipine Tocolysis Regime Policy
Document ID: MATY072 Version: 1.0 Facilitated by: Karen Wakelin, ACMM Issue Date: August 2010 Approved by: Maternity Quality Committee Review date: October 2017 Nifedipine Tocolysis Regime Policy Policy
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Acute and Maintenance Tocolysis Page 1 of 17 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Acute and Maintenance Tocolysis Professional Institutional Original
More informationKofinas Perinatal Providing Care to the Unborn
Alexander D. Kofinas, MD Director, Kofinas Perinatal Associate Professor, Clinical Obstetrics and Gynecology Cornell University, College of Medicine Patient instructions for the use of Indomethacin and
More informationOriginal Article Clinical efficacy of atosiban treatment in late abortion and preterm labour of twin pregnancy
Int J Clin Exp Med 2016;9(2):3946-3952 www.ijcem.com /ISSN:1940-5901/IJCEM0016466 Original Article Clinical efficacy of atosiban treatment in late abortion and preterm labour of twin pregnancy Ya-Juan
More informationTOCOLYTIC DRUGS FOR WOMEN IN PRETERM LABOUR
Clinical Guideline No. 1(B) October 2002 (Replaces Guideline No.1 Beta-agonists and No.1 Ritodrine) TOCOLYTIC DRUGS FOR WOMEN IN PRETERM LBOUR 1. Purpose and scope Preterm birth is the most important single
More informationAtosiban versus usual care for the management of preterm labor
J. Perinat. Med. 35 (2007) 305 33 Copyright by Walter de Gruyter Berlin New York. DOI 0.55/JPM.2007.078 Atosiban versus usual care for the management of preterm labor Peter Husslein, *, Luis Cabero Roura
More informationCOMPARISON OF NEFIDIPINE WITH SOLBUTAMOL AS TOCOLYTIC AGENTS IN PRETERM LABOUR
E:/Biomedica Vol.23 Jul. Dec. 2007/Bio-10 (A) COMPARISON OF NEFIDIPINE WITH SOLBUTAMOL AS TOCOLYTIC AGENTS IN PRETERM LABOUR KIREN K. MALIK Department of Obstetrics and Gynaecology, Fatima Jinnah Medical
More informationA clinical study of feto-maternal outcome of. Isoxsuprine Hydrochloride in preterm labour
Original Research Article A clinical study of feto-maternal outcome of tocolytic agent nifedipine as compared to Isoxsuprine Hydrochloride in preterm labour Farzana Zahir 1*, Kalyan Kumar Nath 2, H H Choudhury
More informationTocolytics. Tocolytics (terbutaline, magnesium sulfate injection) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.06 Subject: Tocolytics Page: 1 of 5 Last Review Date: September 15, 2016 Tocolytics Description Tocolytics
More informationClinical practice evaluation of atosiban in preterm labour management in six European countries
DOI: 10.1111/j.1471-0528.2006.01134.x www.blackwellpublishing.com/bjog Original article Clinical practice evaluation of atosiban in preterm labour management in six European countries P Husslein, a LC
More informationTocolytics for preterm premature rupture of membranes (Review)
(Review) Mackeen AD, Seibel-Seamon J, Grimes-Dennis J, Baxter JK, Berghella V This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane
More informationCOMPARISON BETWEEN NIFEDIPINE AND RITODRINE AS AN EFFECTIVE TOCOLYTIC AGENT FOR PRETERM LABOUR
Original Article COMPARISON BETWEEN NIFEDIPINE AND RITODRINE AS AN EFFECTIVE TOCOLYTIC AGENT FOR PRETERM LABOUR Nadeem Shahzad, 1 Faiqa Saleem, 2 Muhammad Shahid, 3 Aisha Malik 4 Abstract Background: Preterm
More informationMeasurement of betamethasone concentration in maternal serum treated for fetal lung maturity; Is it feasible?
Salim et al. Reproductive Biology and Endocrinology (2016) 14:7 DOI 10.1186/s12958-016-0142-4 RESEARCH Measurement of betamethasone concentration in maternal serum treated for fetal lung maturity; Is it
More informationPreterm Labour and Tocolysis
Title: CLINICAL GUIDELINES ID TAG Preterm Labour and Tocolysis Authors: Designation: Speciality / Division: Directorate: Dr L Bell, Dr K Price, Dr G McKeown, Mr D Sim Trainee, Trainee, CAH Consultant,
More informationComparison of perinatal outcomes between long-term and short-term use of tocolytic agent: a historical cohort study in a single perinatal hospital
doi:10.1111/jog.13104 J. Obstet. Gynaecol. Res. Vol. 42, No. 12: 1680 1685, December 2016 Comparison of perinatal outcomes between long-term and short-term use of tocolytic agent: a historical cohort study
More informationComparison of Efficacy and Safety of Intravenous Labetalol Versus Hydralazine for Management of Severe Hypertension in Pregnancy
https://doi.org/10.1007/s13224-017-1053-9 ORIGINAL ARTICLE Comparison of Efficacy and Safety of Intravenous Labetalol Versus Hydralazine for Management of Severe Hypertension in Pregnancy Purvi Patel 1
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Atosiban 6.75 mg/0.9 ml solution for injection. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ampoule (0.9 ml solution) contains 6.75
More informationAdverse effects of tocolytic therapy
BJOG: an International Journal of Obstetrics and Gynaecology March 2005, Vol. 112, Supplement 1, pp. 74 78 Adverse effects of tocolytic therapy Steve Caritis The rationale for using tocolytics in preterm
More informationEfficacy of Oxytocin Receptors Antagonist, Magnesium Sulfate and Calcium Channel Blockers in Treatment of Preterm Labour
Med. J. Cairo Univ., Vol. 84, No. 1, June: 609-619, 2016 www.medicaljournalofcairouniversity.net Efficacy of Oxytocin Receptors Antagonist, Magnesium Sulfate and Calcium Channel Blockers in Treatment of
More informationPre-term birth occurs when a neonate is birthed or
Susan L. Rideout, RN-C, BSN Pre-term birth occurs when a neonate is birthed or delivered prior to the completion of the 37th week of pregnancy. It s the leading cause of morbidity and the second leading
More information2. Name of the focal point in WHO submitting or supporting the application
NIFEDIPINE Application 1. Summary statement of the proposal for inclusion Nifedipine, a calcium channel blocker already available in WHO Model Formulary 2004, needs an indication for threatened preterm
More informationEfficacy and side effect of ritodrine and magnesium sulfate in threatened preterm labor
Original Article Obstet Gynecol Sci 2018;61(1):63-70 https://doi.org/10.5468/ogs.2018.61.1.63 pissn 2287-8572 eissn 2287-8580 Efficacy and side effect of ritodrine and magnesium sulfate in threatened preterm
More informationThe Treatment of Preterm Labor Using a Portable Subcutaneous Terbutaline Pump
The Treatment of Preterm Labor Using a Portable Subcutaneous Terbutaline Pump D. JEAN SALA, RN, MSN, AND KENNETH J. MOISE, JR., MD The perinatal mortality rate related to preterm delivery has led researchers
More informationAtosiban vs. ritodrine as a tocolytic in external cephalic version at term: a prospective cohort study
J. Perinat. Med. 38 (2010) 23 28 Copyright by Walter de Gruyter Berlin New York. DOI 10.1515/JPM.2010.010 Atosiban vs. ritodrine as a tocolytic in external cephalic version at term: a prospective cohort
More informationManagement of Pregestational and Gestational Diabetes Mellitus
Background and Prevalence Management of Pregestational and Gestational Diabetes Mellitus Pregestational Diabetes - 8 million women in the US are affected, complicating 1% of all pregnancies. Type II is
More informationPost - caesarean section pyrexia and its relation of rupture of membranes and prophylactic antibiotics
MOJ Women s Health Research Article Open Access Post - caesarean section pyrexia and its relation of rupture of membranes and prophylactic antibiotics Abstract Objectives: To determine the incidence of
More informationDrugs used in obstetrics
Drugs used in obstetrics Drugs used in obstetrics Drugs may be used to modify uterine contractions. These include oxytocic drugs used to stimulate uterine contractions both in induction of labour and to
More informationOutcomes of Pregnancies at Risk for Hypertensive Complications Managed Using Impedance Cardiography
Outcomes of Pregnancies at Risk for Hypertensive Complications Managed Using Impedance Cardiography David G. Chaffin, M.D., 1 and Denise G. Webb, RNC, BSN 2 ABSTRACT We assessed the effect of antihypertensive
More informationMagnesium sulfate has an antihypertensive effect on severe pregnancy induced hypertension
Hypertension Research In Pregnancy 11 S. Takenaka et al. ORIGINAL ARTICLE Magnesium sulfate has an antihypertensive effect on severe pregnancy induced hypertension Shin Takenaka 1, Ryu Matsuoka 2, Daisuke
More information1st Department of Obstetrics and Gynecology, Alexandra Maternity Hospital, National and Kapodistrian University of Athens, Athens, Greece.
HJOG An Obstetrics and Gynecology International Journal HJOG 2019, 18 (1), 21-25 Christos Kalantzis, Kalliopi Pappa 1st Department of Obstetrics and Gynecology, Alexandra Maternity Hospital, National and
More informationAdmission/Discharge Form for Infants Born in Please DO NOT mail or fax this form to the CPQCC Data Center. This form is for internal use ONLY.
Selection Criteria Admission/Discharge Form for Infants Born in 2016 To be eligible, you MUST answer YES to at least one of the possible criteria (A-C) A. 401 1500 grams o Yes B. GA range 22 0/7 31 6/7
More informationCHAPTER 12 HYPERTENSION IN SPECIAL GROUPS HYPERTENSION IN PREGNANCY
CHAPTER 12 HYPERTENSION IN SPECIAL GROUPS HYPERTENSION IN PREGNANCY v Mild preeclampsia is managed by close observation of the mother and fetus preferably in hospital. If the diastolic blood pressure remains
More information39 th Annual Perinatal Conference Vanderbilt University December 6, 2013 IUGR. Diagnosis and Management
39 th Annual Perinatal Conference Vanderbilt University December 6, 2013 IUGR Diagnosis and Management Giancarlo Mari, M.D., M.B.A. Professor and Chair Department of Obstetrics and Gynecology University
More informationAnesthetics, Local a / or Anesthesia, Epidural a / or Anesthesia, Obstetrical a / or Pain, Postoperative a / or Postpartum Period a
Appendix 1. Literature Search Databases Years Search Terms Pubmed 01/1966 1. Analgesics, Opioid a / or Opioid-related Disorders a / PsycINFO EMBASE Cochrane 09/2016 or Heroin a / or Heroin Dependence a
More informationEffect of Various Degrees of Maternal Hyperglycemia on Fetal Outcome
ORIGINAL ARTICLE Effect of Various Degrees of Maternal Hyperglycemia on Fetal Outcome ABSTRACT Shagufta Tahir, Shaheen Zafar, Savita Thontia Objective Study design Place & Duration of study Methodology
More informationCyclo-oxygenase (COX) inhibitors for treating preterm labour (Review)
Cyclo-oxygenase (COX) inhibitors for treating preterm labour (Review) King JF, Flenady V, Cole S, Thornton S This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration
More informationResearch Article Magnesium Sulfate as a Second-Line Tocolytic Agent for Preterm Labor: A Randomized Controlled Trial in Kyushu Island
Pregnancy Volume 2011, Article ID 965060, 6 pages doi:10.1155/2011/965060 Research Article Magnesium Sulfate as a Second-Line Tocolytic Agent for Preterm Labor: A Randomized Controlled Trial in Kyushu
More informationIsolated proteinuria in Chinese pregnant women with pre-eclampsia: Results of retrospective observational study
Biomedical Research 2017; 28 (11): 5162-5166 ISSN 0970-938X www.biomedres.info Isolated proteinuria in Chinese pregnant women with pre-eclampsia: Results of retrospective observational study Jing Cai 1,
More informationUpdate on mangement of patent ductus arteriosus in preterm infants. Dr. Trinh Thi Thu Ha
Update on mangement of patent ductus arteriosus in preterm infants Dr. Trinh Thi Thu Ha Outline 1. Overview of PDA 2. Timing of screening PDA? 3. When to treat PDA? Timing of ductal closure Prenatal
More informationMFMU - Background. MFMU - Background MFMU GOALS
MFMU - Background Highlights From The MFM Units Network Ronald Wapner, MD Modern OB management (especially high risk pregnancies) has adopted principles of care, employed pharmaceuticals, applied methodologies
More informationLindsey Tingen, MD Department of Obstetrics and Gynecology, Greenville Health System Greenville, SC
Postpartum IUD Insertion: Continued Usage at Six Months Based on Expulsion and Removal Rates at Greenville Memorial Hospital in the First Year After Adoption of the Practice Lindsey Tingen, MD Department
More informationYou admitted a previously healthy nullipara at 36 weeks gestation who presented with new-onset periorbital edema and is found to have blood pressure
Preeclampsia Case report You admitted a previously healthy nullipara at 36 weeks gestation who presented with new-onset periorbital edema and is found to have blood pressure readings of 150/100 to 155/105
More informationMANAGEMENT OF HYPERTENSION IN PREGNANCY, THE ALGORHITHM
MANAGEMENT OF HYPERTENSION IN PREGNANCY, THE ALGORHITHM Are Particular Anti-hypertensives More Effective or Harmful Than Others in Hypertension in Pregnancy? Existing data is inadequate Methyldopa and
More informationPrevalence of thyroid disorder in pregnancy and pregnancy outcome
Original Research Article Prevalence of thyroid disorder in pregnancy and pregnancy outcome Praveena K.R. 1, Pramod Kumar K.R. 2*, Prasuna K.R. 3, Krishna Kumar TV 4 1 Assistant Professor, Department of
More informationKey words: Preterm labor, oxytocin, oxytocin receptor antagonist, atosiban, randomized clinical trial, tocolysis, prematurity
An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: A randomized, double-blind, placebo-controlled trial with tocolytic rescue Roberto Romero, MD, Baha M. Sibai, MD, Luis Sanchez-Ramos,
More informationMaternal And Fetal Outcome In Pregnancies Complicated With Maternal Cardiac Diseases: Experience At A Tertiary Care Hospital
ISPUB.COM The Internet Journal of Gynecology and Obstetrics Volume 19 Number 1 Maternal And Fetal Outcome In Pregnancies Complicated With Maternal Cardiac Diseases: Experience At A Tertiary Care Hospital
More informationStudy of the role of low dose magnesium Sulphate in Hypertensive Disorders of Pregnancy 1 2
ORIGINAL ARTICLE J Pub Health Med Res 2015;3(2):31-37 Study of the role of low dose magnesium Sulphate in Hypertensive Disorders of Pregnancy 1 2 Shubha C.R. Vailaya, Naveena Kumari M. 1 Chief Consultant
More informationNevada Journal of Public Health, (2010). Vol. 7 Shen et al., 27
Nevada Journal of Public Health, (2010). Vol. 7 Shen et al., 27 Adverse Maternal Outcomes in Nevada: Does Asthma Matter? Jay J. Shen, Ph.D. Department of Health Care Administration and Policy School of
More informationMaternal adverse effects of different antenatal magnesium sulphate regimens for improving maternal and infant outcomes: a systematic review
Bain et al. BMC Pregnancy and Childbirth 2013, 13:195 RESEARCH ARTICLE Open Access Maternal adverse effects of different antenatal magnesium sulphate regimens for improving maternal and infant outcomes:
More informationStroke in Pregnancy. Stroke in Pregnancy 6/23/13
G5#$#Preven*ng#Maternal#Morbidity#and#Mortality#Via# Expanded#Scope#of#Nursing#Prac*ce#As#First#Responder# in#hypertensive#crisis#of#preeclampsia# The$presenter$reports$no$relevant,$influencing$financial$rela5onships.$
More informationGestational Diabetes. Gestational Diabetes:
Gestational Diabetes Detection and Management Steven Gabbe, MD The Ohio State University Medical Center Gestational Diabetes: Detection and Management Learning Objectives: At the conclusion of this presentation,
More informationhydroxyprogesterone caproate Injection (Makena )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationCombined spinalepidural. epidural analgesia in labour (review) By Neda Taghizadeh
Combined spinalepidural versus epidural analgesia in labour (review) By Neda Taghizadeh Cochrane review Cochrane collaboration was founded in 1993 and is named after Archie Cochrane (1909-1988), British
More informationOverview. In Vitro Fertilization: a Success Story
Does IVF cause adverse perinatal outcomes? Paolo Rinaudo *, MD PhD Rebecca A. Jackson %, MD Departments of Ob/Gyn & *Center for Reproductive Sciences & % Epi/Biostats University of California, San Francisco
More informationcardiovascular events when in use in these indications and the outcome of the review is summarised below.
Annex II Scientific conclusions and grounds for revocation or variation as applicable to the terms of the marketing authorisations and detailed explanation for the differences from the PRAC recommendation
More information2/13/2018. Update on Gestational Diabetes. Disclosure. Objectives. I have no financial conflicts of interest.
Update on Gestational Diabetes Lorie M. Harper, MD, MSCI Department of Obstetrics & Gynecology Division of Maternal-Fetal Medicine 2/18/2018 Disclosure I have no financial conflicts of interest. Objectives
More informationMedication Policy Manual. Topic: Makena, hydroxyprogesterone caproate Date of Origin: March 28, 2011
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Policy No: dru255 Topic: Makena, hydroxyprogesterone caproate Date of Origin: March 28, 2011 Revised Date: August
More informationRecommendations for Hospital Quality Measures in 2011:
Pediatric Measures: Recommendations for Hospital Quality Measures in 2011: Based on the input of a group of healthcare stakeholders, the following new hospital measures are recommended: 1) Home Management
More informationHypoglycemia During the 100-g Oral Glucose Tolerance Test: Incidence and Perinatal Significance
During the 100-g Oral Glucose Tolerance Test: Incidence and Perinatal Significance Amir Weissman, MD, Ido Solt, MD, Moshe Zloczower, MD, and Peter Jakobi, MD OBJECTIVE: To estimate and report the incidence
More informationCost-Effectiveness of Ritodrine and Fenoterol for Treatment of Preterm Labor in a Low Middle-Income Country:A Case Study
Volume 11 Number 2 2008 VALUE IN HEALTH Cost-Effectiveness of Ritodrine and Fenoterol for Treatment of Preterm Labor in a Low Middle-Income Country:A Case Study Mihajlo Jakovljevic, MD, Mirjana Varjacic,
More informationGestational Diabetes: An Update on Testing. Kimberlee A McKay, M.D. Avera Medical Group Ob/GYN
Gestational Diabetes: An Update on Testing Kimberlee A McKay, M.D. Avera Medical Group Ob/GYN Gestational Diabetes Increased risks of: Still Birth Hydramnios Should Dystocia Prolonged Labor Preeclampsia
More informationSetting Department of Gynecology and Obstetrics, Cleveland Clinic Foundation (tertiary care academic centre), USA.
Prospective randomized clinical trial of laparoscopically assisted vaginal hysterectomy versus total abdominal hysterectomy Falcone T, Paraiso M F, Mascha E Record Status This is a critical abstract of
More informationAmpicillin/Sulbactam, Cefazolin, or Cefotetan in High-Risk Cesarean Section Patients
Infectious Diseases in Obstetrics and Gynecology 6:220-223 (1998) (C) 1998 Wiley-Liss, Inc. Incidence of Postpartum Endomyometritis Following Single-Dose Antibiotic Prophylaxis With Either Ampicillin/Sulbactam,
More informationVaginal Cleansing prior to Cesarean Section and Post Operative Infectious Morbidity
Vaginal Cleansing prior to Cesarean Section and Post Operative Infectious Morbidity Prof. Dr Syeda Batool Mazhar, Dr. Sara Asad MCH Centre, PIMS, SZABMU, Islamabad, Pakistan Vaginal Cleansing Prior to
More informationGestational Diabetes. Benjamin Byers, D.O., FACOG Center for Maternal and Fetal Care Bryan Physician Network
Gestational Diabetes Benjamin Byers, D.O., FACOG Center for Maternal and Fetal Care Bryan Physician Network Outline Definition Prevalence Risk factors complications Diagnosis Management Nonpharmacologic
More informationMagnesium Sulfate Prophylaxis in Preeclampsia: Evidence From Randomized Trials
CLINICAL OBSTETRICS AND GYNECOLOGY Volume 48, Number 2, 478 488 Ó 2005, Lippincott Williams & Wilkins Magnesium Sulfate Prophylaxis in Preeclampsia: Evidence From Randomized Trials BAHA M. SIBAI, MD Department
More informationDeclaration of conflict of interest
Declaration of conflict of interest Claudio Borghi Lectures fees: Menarini International, Servier International, Recordati International, Ely-Lilly USA, BMS, Boheringer Ingelheim, Novartis Pharma Research
More informationRETIRED: REVIEWED/Revised: 12/14; 10/15; 1/16; 9/16, 10/16, 5/17, 5/18, 9/18
PAGE: 1 of 9 Scope Louisiana Healthcare Connections (LHCC) Medical Department Purpose To provide medical necessity criteria for obstetrical Home Health programs offered by vendors such as Optum Obstetrical
More informationUterine Contractility Symposium. Oxytocin antagonists: clinical and scientific considerations
Uterine Contractility Symposium Oxytocin antagonists: clinical and scientific considerations Steven Thornton *, Manu Vatish and Donna Slater Department of Biological Sciences, University of Warwick, Coventry
More informationThe Ever-Changing Approaches to Diabetes in Pregnancy
The Ever-Changing Approaches to Diabetes in Pregnancy Kirsten E. Salmeen, MD Assistant Professor Obstetrics, Gynecology & Reproductive Sciences Maternal-Fetal Medicine I have nothing to disclose. Approaches
More informationThe New GDM Screening Guidelines. Jennifer Klinke MD, FRCPC Endocrinologist and Co director RCH Diabetes in Pregnancy Program
The New GDM Screening Guidelines Jennifer Klinke MD, FRCPC Endocrinologist and Co director RCH Diabetes in Pregnancy Program Disclosures Current participant (RCH site) for MiTy study Metformin in women
More informationThe Effect of Valvular Heart Diseases on Maternal and Fetal Outcome of Pregnancy Nada Salih Ameen*,Nawfal Fawzi Anwer**
THE VALVULAR IRAQI POSTGRADUATE HEART DISEASES MEDICAL AND JOURNAL PREGNANCY The Effect of Valvular Heart Diseases on Maternal and Fetal Outcome of Pregnancy Nada Salih Ameen*,Nawfal Fawzi Anwer** ABSTRACT:
More informationPregnancy Smoking Intervention in NE Tennessee: Effectiveness Data from the First Two Years of TIPS
Pregnancy Smoking Intervention in NE Tennessee: Effectiveness Data from the First Two Years of TIPS Beth A. Bailey, PhD Associate Professor of Family Medicine Director, Tennessee Intervention for Pregnant
More informationResearch Article Timing of Caffeine Therapy and Neonatal Outcomes in Preterm Infants: A Retrospective Study
International Pediatrics Volume 2016, Article ID 9478204, 6 pages http://dx.doi.org/10.1155/2016/9478204 Research Article Timing of Caffeine Therapy and Neonatal Outcomes in Preterm Infants: A Retrospective
More informationCOMPLICATIONS OF PRE-GESTATIONAL AND GESTATIONAL DIABETES IN SAUDI WOMEN: ANALYSIS FROM RIYADH MOTHER AND BABY COHORT STUDY (RAHMA)
COMPLICATIONS OF PRE-GESTATIONAL AND GESTATIONAL DIABETES IN SAUDI WOMEN: ANALYSIS FROM RIYADH MOTHER AND BABY COHORT STUDY (RAHMA) Prof. Hayfaa Wahabi, King Saud University, Riyadh Saudi Arabia Hayfaa
More informationSAMPLE. V.12.1 Special Report: Very Low Birthweight Neonates. I. Introduction
I. Introduction V.12.1 Special Report: Very Low Birthweight Neonates The delivery of a very low birth weight infant continues to present many challenges to families and health care providers in spite of
More informationBy: Armend Lokku Supervisor: Dr. Lucia Mirea. Maternal-Infant Care Research Center, Mount Sinai Hospital
By: Armend Lokku Supervisor: Dr. Lucia Mirea Maternal-Infant Care Research Center, Mount Sinai Hospital Background My practicum placement was at the Maternal-Infant Care Research Center (MiCare) at Mount
More informationAcute Postpartum Pulmonary Edema: A Case Report
Postpartum pulmonary edema 157 Acute Postpartum Pulmonary Edema: A Case Report Min-Po Ho 1, Wing-Keung Cheung 2, Kaung-Chau Tsai 1 Acute pulmonary edema after pregnancy is rare. Pulmonary emobolism, pneumonia,
More informationLabour Epidurals and Maternal Pyrexia
Labour Epidurals and Maternal Pyrexia Katherine W. Arendt, MD Associate Professor of Anesthesiology Mayo Clinic, Rochester, Minnesota Obstetric Anaesthetists Association November 2, 2015 2013 MFMER slide-1
More informationVishwanath Pattan Endocrinology Wyoming Medical Center
Vishwanath Pattan Endocrinology Wyoming Medical Center Disclosure Holdings in Tandem Non for this Training Introduction In the United States, 5 to 6 percent of pregnancies almost 250,000 women are affected
More informationSWISS SOCIETY OF NEONATOLOGY. Spontaneous intestinal perforation or necrotizing enterocolitis?
SWISS SOCIETY OF NEONATOLOGY Spontaneous intestinal perforation or necrotizing enterocolitis? June 2004 2 Stocker M, Berger TM, Neonatal and Pediatric Intensive Care Unit, Children s Hospital of Lucerne,
More informationBasic Doppler Assessment of Fetal Distress
Basic Doppler Assessment of Fetal William J. Polzin, M.D. Co-Director, Fetal Care Center of Cincinnati Director, Division of Maternal-Fetal Medicine Good Samaritan Hospital Cincinnati, OH No Relevant Disclosures
More informationThe high risk neonate
The high risk neonate Infant classification by gestational (postmenstrual) age Preterm. Less than 37 completed weeks (259 days). Term. Thirty-seven to 416/7 weeks (260-294 days). Post-term. Forty-two weeks
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Crinone, Endometrin) Reference Number: CP.CPA.03 Effective Date: 11.16.16 Last Review Date: 08.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy
More informationLEARNING OBJECTIVES 2/20/2017
HYPERTENSION IN PREGNANCY: PREVENTING SEVERE MATERNAL MORBIDITY & MORTALITY THROUGH THE IMPLEMENTATION OF EVIDENCED BASED PROTOCOLS Laura Senn, RN, PhD, CNS Sutter Medical Center, Sacramento LEARNING OBJECTIVES
More informationHazards and Benefits of Postnatal Steroids. David J. Burchfield, MD Professor and Chief, Neonatology University of Florida
Hazards and Benefits of Postnatal Steroids David J. Burchfield, MD Professor and Chief, Neonatology University of Florida Disclosures I have no financial affiliations or relationships to disclose. I will
More informationAcyclovir suppression to prevent clinical recurrences at delivery after first episode genital herpes in pregnancy: an open-label trial
Infect Dis Obstet Gynecol 2001;9:75 80 Acyclovir suppression to prevent clinical recurrences at delivery after first episode genital herpes in pregnancy: an open-label trial L. Laurie Scott 1, Lisa M.
More informationCMQCC Preeclampsia Tool Kit: Hypertensive Disorders Across the Lifespan
CMQCC Preeclampsia Tool Kit: Hypertensive Disorders Across the Lifespan Carol J Harvey, MS, BSN, RNC-OB, C-EFM, CS Northside Hospital Atlanta Cherokee - Forsyth New! Improving Health Care Response to Preeclampsia:
More informationPresent-on-Admission (POA) Coding
1 Present-on-Admission (POA) Coding Michael Pine, MD, MBA Michael Pine and Associates, Inc 2 POA and Coding Guidelines (1) Unless otherwise specified, a POA modifier must be assigned to each principal
More informationUNIT TWO: OBSTETRICS EDUCATIONAL TOPIC 17: MEDICAL AND SURGICAL COMPLICATIONS OF PREGNANCY
UNIT TWO: OBSTETRICS EDUCATIONAL TOPIC 17: MEDICAL AND SURGICAL COMPLICATIONS OF PREGNANCY Rationale: Medical and surgical conditions may alter the course of pregnancy. Likewise, pregnancy may have an
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Crinone, Endometrin ) Reference Number: CP.CPA.03 Effective Date: 11.16.16 Last Review Date: 8.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of
More informationProject TEACH Addressing Tobacco Treatment for Pregnant Women Jan Blalock, Ph.D.
Project TEACH Addressing Tobacco Treatment for Pregnant Women Jan Blalock, Ph.D. Prevalence of Smoking and Cessation During Pregnancy In 2014, 14% in women with Medicaid coverage versus 3.6% of women with
More informationAcyclovir suppression to prevent recurrent genital herpes at delivery
Infect Dis Obstet Gynecol 2002;10:71 77 Acyclovir suppression to prevent recurrent genital herpes at delivery L. L. Scott 1, L. M. Hollier 1, D. McIntire 1, P. J. Sanchez 2, G. L. Jackson 2 and G. D. Wendel,
More information